Healthcare
Monroe Biomedical Research
Headquarters
Monroe, NC
Website
Investment Date
August 2023
Revenue Growth
66.7% CAGR (over the four years prior to closing)
New Harbor Capital originally established clinical trial research as a thesis area in 2019 and has continued to evaluate opportunities within the sector ever since. There is significant opportunity within the clinical trial space as it is rapidly growing and highly fragmented, with an estimated 96 percent of the over 20,000 active sites operating as independent standalone sites. The pre-clinical drug pipeline has grown over 50 percent from 2015 through 2020, and the number of sites utilized per trial has increased as delays due to slow or minimal patient enrollment remains a primary issue in the industry. New Harbor has been targeting innovative clinical trial models focused on enrolling diverse patient bases and having broad therapeutic expertise, as opposed to a singular therapeutic focus.
New Harbor was first introduced to Monroe Biomedical Research (“MBR”, “the Company”) in March 2023. We found MBR to be unique from other clinical trial site businesses based on its diverse therapeutic expertise and experience in patient recruitment and trial execution, which are the key challenges within the drug development ecosystem at the moment. Monroe’s team of founders also presented a great opportunity to invest alongside partners who share our vision and values.
Monroe Biomedical Research was founded in 2015 by Suvi Gross, Ben Karsai, and Dr. Greg Feldman, and is headquartered outside of Charlotte in Monroe, North Carolina. The Company has a history of success in achieving enrollment targets, including investigations into treatments for pulmonary, metabolic, cardiological, psychiatric, and infectious diseases, as well as vaccine studies.
“We are thrilled to be partnered with New Harbor Capital. New Harbor’s expertise and track record of scaling founder-owned, multi-site healthcare companies will be extremely valuable as we seek to expand our reach and achieve the vision we have for the business.”
Suvi Gross
Founder and President of Monroe Biomedical Research*
Our investment management plan focuses on scaling the Company’s existing infrastructure, broadening, and growing its therapeutic focus areas and expanding its geographic footprint. We look forward to building upon MBR’s leading reputation and innovative clinical trial model to build one of the premier clinical trial site management organizations in the country.
*Certain statements about New Harbor Capital made by portfolio company executives herein are intended to illustrate New Harbor Capital’s business relationship with such persons, including with respect to New Harbor Capital’s facilities as a business partner, rather than New Harbor Capital’s capabilities or expertise with respect to investment advisory services. Portfolio company executives were not compensated in connection with their participation, although they generally receive compensation and investment opportunities in connection with their portfolio company roles, and in certain cases are also owners of portfolio company securities and/or investors in New Harbor Capital-sponsored vehicles. Such compensation and investments subject participants to potential conflicts of interest in making the statements herein.
See More Investment Stories Like This
Bloom Health Centers
Healthcare
Bloom Health Centers is a comprehensive mental healthcare group in the Mid-Atlantic.
LGM Pharma
Healthcare
LGM Pharma is an API company involved in distribution of cGMP pharma ingredients and other value-added services supporting pharmaceutical companies.
Access Infusion Care
Healthcare
Access Infusion Care is a diversified specialty and infusion pharmacy services provider focused on providing high-quality infusion therapies for patients in the home and suite settings.